The B.C. COVID-19 Dashboard has been retired and will no longer be updated.Purpose: These data can be used for visual or reference purposes.British Columbia, Canada COVID-19 Regional Summary Date are from the British Columbia Centre for Disease Control, Provincial Health Services Authority and the British Columbia Ministry of Health.

These data represent the British Columbia Health Service Delivery Area and Health Authority 7-day Moving Average COVID-19 case data.

These data were made specifically for the British Columbia COVID-19 Dashboard.

Terms of use, disclaimer and limitation of liabilityAlthough every effort has been made to provide accurate information, the Province of British Columbia, including the British Columbia Centre for Disease Control, the Provincial Health Services Authority and the British Columbia Ministry of Health makes no representation or warranties regarding the accuracy of the information in the dashboard and the associated data, nor will it accept responsibility for errors or omissions. Data may not reflect the current situation, and therefore should only be used for reference purposes. Access to and/or content of these data and associated data may be suspended, discontinued, or altered, in part or in whole, at any time, for any reason, with or without prior notice, at the discretion of the Province of British Columbia.Anyone using this information does so at his or her own risk, and by using such information agrees to indemnify the Province of British Columbia, including the British Columbia Centre for Disease Control, the Provincial Health Services Authority and the British Columbia Ministry of Health and its content providers from any and all liability, loss, injury, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information on this website.Dashboard Updates - GeneralData are updated up to the previous Saturday. Weekly metrics reflect the latest full week, Sunday to Saturday. The “Currently Hospitalized” and “Currently in Critical Care” reflect daily volumes on the Thursday.Data Notes - GeneralThe following data notes define the indicators presented on the public dashboard and describe the data sources involved. Data changes as new cases are identified, characteristics of reported cases change or are updated, and data corrections are made. Specific values may therefore fluctuate in response to underlying system changes. As such, case, hospitalization, deaths, testing and vaccination counts and rates may not be directly comparable to previously published reports. For the latest caveats about the data, please refer to the most recent BCCDC Surveillance Report located at: www.bccdc.ca/health-info/diseases-conditions/covid-19/dataData SourcesLaboratory data are supplied by the B.C. Centre for Disease Control (BCCDC) Public Health Laboratory; tests performed for other provinces have been excluded. See “Data Over Time” for more information on changes to the case definition.Total COVID-19 cases include lab-confirmed, lab-probable and epi-linked cases. Case definitions can be found at: https://www.bccdc.ca/health-professionals/clinical-resources/case-definitions/covid-19-(novel-coronavirus). Currently hospitalized and critical care hospitalizations data are received from Provincial COVID-19 Monitoring Solution, Provincial Health Services Authority. See “Data Over Time” for more information on previous data sources.Vaccine data are received from the B.C. Ministry of Health.Mortality data are received from Vital Statistics, B.C. Ministry of Health. See Data Over Time for more information on precious data sources.Laboratory data is supplied by the B.C. Centre for Disease Control Public Health Laboratory and the Provincial Lab Information Solution (PLIS); tests performed for other provinces have been excluded.Critical care hospitalizations are provided by the health authorities to PHSA on a daily basis. BCCDC/PHSA/B.C. Ministry of Health data sources are available at the links below:Cases Totals (spatial)Case DetailsLaboratory Testing InformationRegional Summary DataData Over TimeThe number of laboratory tests performed and positivity rate over time are reported by the date of test result. See “Laboratory Indicators” section for more details.Laboratory confirmed cases are reported based on the client's first positive lab result.As of April 2, 2022, cases include laboratory-diagnosed cases (confirmed and probable) funded under Medical Services Plan.From January 7, 2021 to April 1, 2022, cases included those reported by the health authorities and those with positive laboratory results reported to the BCCDC. The number of cases over time is reported by the result date of the client's first positive lab result where available; otherwise by the date they are reported to public health. Prior to April 2, 2022, total COVID-19 cases included laboratory-diagnosed cases (confirmed and probable) as well as epi-linked cases. Prior to June 4, 2020, the total number of cases included only laboratory-diagnosed cases.As of January 14, 2022, the data source for "Currently Hospitalized" has changed to better reflect hospital capacity. Comparisons to numbers before this date should not be made.As of April 2, 2022, death is defined as an individual who has died from any cause, within 30 days of a first COVID-19 positive lab result date. Prior to April 22, 2022, death information was collected by Regional Health Authorities and defined as any death related to COVID-19. Comparisons between these time periods are not advised.Epidemiologic Indicators"Currently Hospitalized" is the number of people who test positive for COVID-19 through hospital screening practices, regardless of the reason for admission, as recorded in PCMS on the day the dashboard is refreshed. It is reported by the hospital in which the patient is hospitalized, rather than the patient's health authority of residence.Critical care values (intensive care units, high acuity units, and other critical care surge beds) include individuals who test positive for COVID-19 and are in critical care, as recorded in PCMS.The 7-day moving average is an average daily value over the 7 days up to and including the selected date. The 7-day window moved - or changes - with each new day of data. It is used to smooth new daily case and death counts or rates to mitigate the impact of short-term fluctuations and to more clearly identify the most recent trend over time.The following epidemiological indicators are included in the provincial case data file:Date: date of the client's first positive lab result.HA: health authority assigned to the caseSex: the sex of the clientAge_Group: the age group of the clientClassification_Reported: whether the case has been lab-diagnosed or is epidemiologically linked to another caseThe following epidemiological indicators are included in the regional summary data file:Cases_Reported: the number of cases for the health authority (HA) and health service delivery area (HSDA)Cases_Reported_Smoothed: Seven day moving average for reported casesLaboratory IndicatorsTests represent the number of all COVID-19 tests reported to the BCCDC Public Helath Laboratory since testing began mid-January 2020. Only tests for residents of B.C. are included.COVID-19 positivity rate is calculated for each day as the ratio of 7-day rolling average of number of positive specimens to 7-day rolling average of the total number of specimens tested (positive, negative, indeterminate and invalid). A 7-day rolling average applied to all testing data corrects for uneven data release patterns while accurately representing the provincial positivity trends. It avoids misleading daily peaks and valleys due to varying capacities and reporting cadences.Turn-around time is calculated as the daily average time (in hours) between specimen collection and report of a test result. Turn-around time includes the time to ship specimens to the lab; patients who live farther away are expected to have slightly longer average turn around times.The rate of COVID-19 testing per million population is defined as the cumulative number of people tested for COVID-19/B.C. population x 1,000,000. B.C. Please note: the same person may be tested multiple times, thus it is not possible to derive this rate directly from the number of cumulative tests reported on the B.C. COVID-19 Dashboard.Testing context: COVID-19 diagnostic testing and laboratory test guidelines have changed in British Columbia over time. B.C.'s testing strategy has been characterized by four phases: 1) Exposure-based testing (start of pandemic), 2) Targeted testing (March 16, 2020), 3) Expanded testing (April 9, 2020), 4) Symptom-based testing (April 21, 2020), and 5) Symptom-based testing for targeted populations (a-are at risk of more severe disease and/or b-live or work in high-risk settings such as healthcare workers) and Rapid Antigen Tests deployment (January 18, 2022). Due to changes in testing strategies in BC in 2022, focusing on targeted higher risk populations, current case counts are an underestimate of the true number of COVID-19 cases in BC and may not be representative of the situation in the community.
The following laboratory indicators are included in the provincial laboratory data file:New_Tests: the number of new COVID-19 testsTotal_Tests: the total number of COVID-19 testsPositivity: the positivity rate for COVID-19 testsTurn_Around: the turnaround time for COVID-19 testsBC Testing Rate: Total PCR + POC tests per day (excluding POC that were confirmed by PCR within 7 days) / Population using BC Stats PEOPLE2021 population projections for the year 2022 * 100,000.Health Authority AssignmentCases are reported by health authority of residence.As of April 2, 2022, cases are reported based on the address provided at the time of testing; when not available, by location of the provider ordering the lab test.As of April 2, 2022,

The B.C. COVID-19 Dashboard has been retired and will no longer be updated.Purpose: These data can be used for visual or reference purposes.British Columbia COVID-19 B.C. & Canadian Testing Rates are obtained from the Public Health Agency of Canada’s Daily Epidemiologic Update site: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html.These data were made specifically for the British Columbia COVID-19 Dashboard.

Terms of use, disclaimer and limitation of liabilityAlthough every effort has been made to provide accurate information, the Province of British Columbia, including the British Columbia Centre for Disease Control, the Provincial Health Services Authority and the British Columbia Ministry of Health makes no representation or warranties regarding the accuracy of the information in the dashboard and the associated data, nor will it accept responsibility for errors or omissions. Data may not reflect the current situation, and therefore should only be used for reference purposes. Access to and/or content of these data and associated data may be suspended, discontinued, or altered, in part or in whole, at any time, for any reason, with or without prior notice, at the discretion of the Province of British Columbia.Anyone using this information does so at his or her own risk, and by using such information agrees to indemnify the Province of British Columbia, including the British Columbia Centre for Disease Control, the Provincial Health Services Authority and the British Columbia Ministry of Health and its content providers from any and all liability, loss, injury, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information on this website.Dashboard Updates - GeneralData are updated up to the previous Saturday. Weekly metrics reflect the latest full week, Sunday to Saturday. The “Currently Hospitalized” and “Currently in Critical Care” reflect daily volumes on the Thursday.Data Notes - GeneralThe following data notes define the indicators presented on the public dashboard and describe the data sources involved. Data changes as new cases are identified, characteristics of reported cases change or are updated, and data corrections are made. Specific values may therefore fluctuate in response to underlying system changes. As such, case, hospitalization, deaths, testing and vaccination counts and rates may not be directly comparable to previously published reports. For the latest caveats about the data, please refer to the most recent BCCDC Surveillance Report located at: www.bccdc.ca/health-info/diseases-conditions/covid-19/dataData SourcesLaboratory data are supplied by the B.C. Centre for Disease Control (BCCDC) Public Health Laboratory; tests performed for other provinces have been excluded. See “Data Over Time” for more information on changes to the case definition.Total COVID-19 cases include lab-confirmed, lab-probable and epi-linked cases. Case definitions can be found at: https://www.bccdc.ca/health-professionals/clinical-resources/case-definitions/covid-19-(novel-coronavirus). Currently hospitalized and critical care hospitalizations data are received from Provincial COVID-19 Monitoring Solution, Provincial Health Services Authority. See “Data Over Time” for more information on previous data sources.Vaccine data are received from the B.C. Ministry of Health.Mortality data are received from Vital Statistics, B.C. Ministry of Health. See Data Over Time for more information on precious data sources.Laboratory data is supplied by the B.C. Centre for Disease Control Public Health Laboratory and the Provincial Lab Information Solution (PLIS); tests performed for other provinces have been excluded.Critical care hospitalizations are provided by the health authorities to PHSA on a daily basis. BCCDC/PHSA/B.C. Ministry of Health data sources are available at the links below:Cases Totals (spatial)Case DetailsLaboratory Testing InformationRegional Summary DataData Over TimeThe number of laboratory tests performed and positivity rate over time are reported by the date of test result. See “Laboratory Indicators” section for more details.Laboratory confirmed cases are reported based on the client's first positive lab result.As of April 2, 2022, cases include laboratory-diagnosed cases (confirmed and probable) funded under Medical Services Plan.From January 7, 2021 to April 1, 2022, cases included those reported by the health authorities and those with positive laboratory results reported to the BCCDC. The number of cases over time is reported by the result date of the client's first positive lab result where available; otherwise by the date they are reported to public health. Prior to April 2, 2022, total COVID-19 cases included laboratory-diagnosed cases (confirmed and probable) as well as epi-linked cases. Prior to June 4, 2020, the total number of cases included only laboratory-diagnosed cases.As of January 14, 2022, the data source for "Currently Hospitalized" has changed to better reflect hospital capacity. Comparisons to numbers before this date should not be made.As of April 2, 2022, death is defined as an individual who has died from any cause, within 30 days of a first COVID-19 positive lab result date. Prior to April 22, 2022, death information was collected by Regional Health Authorities and defined as any death related to COVID-19. Comparisons between these time periods are not advised.Epidemiologic Indicators"Currently Hospitalized" is the number of people who test positive for COVID-19 through hospital screening practices, regardless of the reason for admission, as recorded in PCMS on the day the dashboard is refreshed. It is reported by the hospital in which the patient is hospitalized, rather than the patient's health authority of residence.Critical care values (intensive care units, high acuity units, and other critical care surge beds) include individuals who test positive for COVID-19 and are in critical care, as recorded in PCMS.The 7-day moving average is an average daily value over the 7 days up to and including the selected date. The 7-day window moved - or changes - with each new day of data. It is used to smooth new daily case and death counts or rates to mitigate the impact of short-term fluctuations and to more clearly identify the most recent trend over time.The following epidemiological indicators are included in the provincial case data file:Date: date of the client's first positive lab result.HA: health authority assigned to the caseSex: the sex of the clientAge_Group: the age group of the clientClassification_Reported: whether the case has been lab-diagnosed or is epidemiologically linked to another caseThe following epidemiological indicators are included in the regional summary data file:Cases_Reported: the number of cases for the health authority (HA) and health service delivery area (HSDA)Cases_Reported_Smoothed: Seven day moving average for reported casesLaboratory IndicatorsTests represent the number of all COVID-19 tests reported to the BCCDC Public Helath Laboratory since testing began mid-January 2020. Only tests for residents of B.C. are included.COVID-19 positivity rate is calculated for each day as the ratio of 7-day rolling average of number of positive specimens to 7-day rolling average of the total number of specimens tested (positive, negative, indeterminate and invalid). A 7-day rolling average applied to all testing data corrects for uneven data release patterns while accurately representing the provincial positivity trends. It avoids misleading daily peaks and valleys due to varying capacities and reporting cadences.Turn-around time is calculated as the daily average time (in hours) between specimen collection and report of a test result. Turn-around time includes the time to ship specimens to the lab; patients who live farther away are expected to have slightly longer average turn around times.The rate of COVID-19 testing per million population is defined as the cumulative number of people tested for COVID-19/B.C. population x 1,000,000. B.C. Please note: the same person may be tested multiple times, thus it is not possible to derive this rate directly from the number of cumulative tests reported on the B.C. COVID-19 Dashboard.Testing context: COVID-19 diagnostic testing and laboratory test guidelines have changed in British Columbia over time. B.C.'s testing strategy has been characterized by four phases: 1) Exposure-based testing (start of pandemic), 2) Targeted testing (March 16, 2020), 3) Expanded testing (April 9, 2020), 4) Symptom-based testing (April 21, 2020), and 5) Symptom-based testing for targeted populations (a-are at risk of more severe disease and/or b-live or work in high-risk settings such as healthcare workers) and Rapid Antigen Tests deployment (January 18, 2022). Due to changes in testing strategies in BC in 2022, focusing on targeted higher risk populations, current case counts are an underestimate of the true number of COVID-19 cases in BC and may not be representative of the situation in the community.
The following laboratory indicators are included in the provincial laboratory data file:New_Tests: the number of new COVID-19 testsTotal_Tests: the total number of COVID-19 testsPositivity: the positivity rate for COVID-19 testsTurn_Around: the turnaround time for COVID-19 testsBC Testing Rate: Total PCR + POC tests per day (excluding POC that were confirmed by PCR within 7 days) / Population using BC Stats PEOPLE2021 population projections for the year 2022 * 100,000.Health Authority AssignmentCases are reported by health authority of residence.As of April 2, 2022, cases are reported based on the address provided at the time of testing; when not available, by location of the provider ordering the lab test.As of April 2, 2022, cases who reported having an address outside of B.C. are not included.Prior to April 2, 2022, when

This dataset provides Canadians and researchers with preliminary data on the confirmed cases of coronavirus (COVID-19) in Canada. Given the rapidly-evolving nature of this situation, these data are considered preliminary. The dataset was downloaded from Statistics Canada as a CSV file. Due to the size of the data file, it was imported into SPSS from which 5 CSV files were exported based on the region variable. The regions are Atlantic, Quebec, Ontario and Nunavut, Prairies and Northwest Territories, and British Columbia and Yukon. This dataset is a custom extraction of Preliminary dataset on confirmed cases of COVID-19, Public Health Agency of Canada

BackgroundClose-contact rates are thought to be a driving force behind the transmission of many infectious respiratory diseases. Yet, contact rates and their relation to transmission and the impact of control measures, are seldom quantified. We quantify the response of contact rates, reported cases and transmission of COVID-19, to public health contact-restriction orders, and examine the associations among these three variables in the province of British Columbia, Canada.MethodsWe derived time series data for contact rates, daily cases and transmission of COVID-19 from a social contacts survey, reported case counts and by fitting a transmission model to reported cases, respectively. We used segmented regression to investigate impacts of public health orders; Pearson correlation to determine associations between contact rates and transmission; and vector autoregressive modeling to quantify lagged associations between contacts rates, daily cases, and transmission.ResultsDeclines in contact rates and transmission occurred concurrently with the announcement of public health orders, whereas declines in cases showed a reporting delay of about 2 weeks. Contact rates were a significant driver of COVID-19 and explained roughly 19 and 20% of the variation in new cases and transmission, respectively. Interestingly, increases in COVID-19 transmission and cases were followed by reduced contact rates: overall, daily cases explained about 10% of the variation in subsequent contact rates.ConclusionWe showed that close-contact rates were a significant time-series driver of transmission and ultimately of reported cases of COVID-19 in British Columbia, Canada and that they varied in response to public health orders. Our results also suggest possible behavioral feedback, by which increased reported cases lead to reduced subsequent contact rates. Our findings help to explain and validate the commonly assumed, but rarely measured, response of close contact rates to public health guidelines and their impact on the dynamics of infectious diseases.

Baseline characteristics of COVID-19 cases, negative controls, and untested controls.

Context

As we enter into the latter half of the second year of the Coronavirus pandemic, transmission has become the keyword as more variants emerge. In this dataset, I thought to shed some light on the relationship between transmission types and death rates. This dataset contains the number of cases by region in Canada in 2021 by their respective transmission methods and death rates. I also added the perceived health by region in Canada in 2020 as compared to 2019.

Content

The dataset consists of two csv files: transmission & death.csv and Perceived Health.csv.

transmission & death.csv: Case counts by region in Canada categorized by transmission methods and death status. This data is provided by the Public Health Agency of Canada. The original data set contains age and gender details, which I combined columns into one to focus on the transmission vs. death investigation. This file contains case counts from January 15, 2020 to September 5, 2021.

Perceived Health.csv is the perceived health by region in Canada based on the Canadian Community Health Survey released on September 8, 2021.

Column Description

transmission & death dataset transmission & death.csv:

Geography: For the purpose of this study, geography is the Canadian regions of Atlantic, Quebec, Ontario and Nunavut, Prairies and Northwest Territories, and British Columbia and Yukon

Transmission: For the purpose of this study, transmission types are community exposures, travel exposures and not stated

Death statuses: For this study, death statuses are deceased, not deceased and not stated

Perceived Health dataset Perceived Health.csv:

Geography: In this file, geography is broken down into Newfoundland and Labrador, Prince Edward Island, Nova Scotia, New Brunswick, Quebec, Ontario, Manitoba, Saskatchewan, Albert, and British Columbia

Indicators: Perceived health is broken down into very good or excellent and fair or poor

Age groups are broken down into 12 to 17 years, 18 to 34 years, 35 to 49 years, 50 to 64 years, and 65 years and over

Acknowledgements

Data provided for public use by Statistics Canada.

Inspiration

This dataset is meant to gain insight into the severity of symptoms of the coronavirus, as it relates to the type of transmission or the perceived health of the region in question.

As of April 15, 2023, there had been a total of around 51,921 deaths attributed to COVID-19 in Canada. As of this time, every province and territory has reported deaths, with Quebec and Ontario reporting the highest numbers.

COVID-19 in Canada Canada has recorded almost 4.65 million coronavirus cases since the first infection in the country was confirmed on January 25, 2020. The number of cases by province shows that Ontario and Quebec have been the most severely affected. The number of daily new cases reached record highs at the end of 2021 and began to decrease as spring arrived in 2022.

COVID-19 vaccinations in Canada Seven COVID-19 vaccines have now been approved for use in Canada and vaccines are widely available. As of January 1, 2023 around 83 percent of the Canadian population had received at least one dose of a COVID-19 vaccine. The provinces with the highest share of people fully vaccinated against COVID-19 are Newfoundland and Labrador and Nova Scotia. However, Ontario and Quebec are the provinces with the highest total number of people vaccinated.

Comorbidities in the year prior to index date for COVID-19 cases, negative controls, and untested controls.

This dataset includes tweets from provincial and territorial government officials. In cases when a health official does not use Twitter (e.g. Dr. Bonnie Henry), other official accounts for the province or territory have been substituted. The dataset does not include tweets from federal government officials. The tweet IDs were collected using Documenting the Now's Twarc library (https://github.com/DocNow/twarc). The date of the earliest available tweet is different for each handle. The date of the latest available tweet will not be later than the upload date for each file. See the file-level information below. The tweet ids were extracted from the raw JSON files retrieved from Twitter using Twarc. However, Twitter's terms of use do not permit the sharing of the raw JSON files for this dataset. The raw JSON files can be retrieved from Twitter, provided the content is still available, using the 'hydrate' command within Twarc. The researchers retained the source JSON files and may be contacted by other researchers if they wish to access them. The files of tweet ids will be updated over time and this metadata, the files and this readme.txt file will be updated accordingly. Raw JSON files were harvested using Twarc's 'timeline' command. The 'timeline' command retrieves the most recent tweets from the specified handle, to a maximum of approximately 3,300 tweets. The data for each handle was collected approximately weekly, starting in January 2021. In order not to lose earlier tweets, we concatenated the JSON for each new 'timeline' crawl to the earlier crawls and de-duplicated the combined JSON using Twarc's 'deduplicate' command. We then used Twarc's 'dehydrate' command to extract just the tweet ids from the deduplicate JSON file. Finally, we sorted the tweet ids numerically so that they would appear in ascending date order. The basic workflow looks like: twarc timeline --> concatenate JSON files --> deduplicate resulting JSON file --> dehydrate tweet ids --> sort tweet ids. The Twitter handles include: @ArrudaHoracio: Dr. Horacio Arruda, Directeur national de santé publique et SMA en santé publique MSSS Québec. Tweets in this file start on 2013-03-11. @CMOH_Alberta: Dr. Deena Hinshaw, Alberta’s Chief Medical Officer of Health. Tweets in this file start on 2020-03-26. @CMOH_NL: Dr. Janice Fitzgerald, Newfoundland and Labrador's Chief Medical Officer of Health. Tweets in this file start on 2020-04-27. @GOVofNUNAVUT: Government of Nunavut. Tweets in this file start on 2018-08-20. @GlavineLeo: Leo Glavine, MLA Kings West, Nova Scotia, Minister of Health and Wellness, Minister of Seniors. Tweets in this file start on 2017-04-17. @HealthNS: Nova Scotia Health. Tweets in this file start on 2019-05-D8. @Johnrockdoc: John Haggie, Newfoundland and Labrador's Minister, Health & Community Services. Tweets in this file start on 2020-01-19. @IainTRankin: Iain Rankin, Premier of Nova Scotia from 2021-02-23. MLA for Timberlea-Prospect. Tweets in this file start on 2012-08-08. @MLAStefanson: Heather Stefanson, Manitoba's Minister of Health and Seniors Care, MLA for Tuxedo Tweets in this file start on 2012-02-11. @MerrimanPaul: Paul Merriman. Saskatchewan's Minister of Social Services. Tweets in this file start on 2018-11-18. @MinistreMcCann: Danielle McCann. Députée de Sanguinet - Ministre de l'Enseignement supérieur. Tweets in this file start on 2019-03-14. @NBHealth: New Brunswick Department of Health. Tweets in this file start on 2013-02-26. @NWT_CPHO: Kami Kandola, Northwest Territories Chief Public Officer of Health. Tweets in this file start on 2013-10-16. @PFrostOldCrow: Pauline Frost Yukon MLA for Vuntut Gwich'in. Minister of Health and Social Services, Environment and Minister responsible for the Yukon Housing Corporation. Tweets in this file start on 2016-08-05. @SaskHealth: Saskatchewan Health Authority official twitter account. Tweets in this file start on 2020-03-15. @ShephardDorothy: Dorothy Shephard, Minister of Health for New Brunswick. Tweets in this file start on 2016-04-16. @StephenMcNeil: Stephen McNeil, Premier of Nova Scotia from 2013-10-23 to 2021-02-23. MLA for Annapolis. Tweets in this file start on 2017-05-05. @adriandix: Adrian Dix, MLA for Vancouver-Kingsway and BC Minister of Health. Tweets in this file start on 2019-09-20. @celliottability: Christine Elliott, Deputy Premier of Ontario and Minister of Health, MPP for Newmarket-Aurora. Tweets in this file start on 2018-02-24. @epdevilla: Dr. Eileen de Villa, Toronto's Medical Officer of Health. Tweets in this file start on 2013-02-21. @jsjaylward: James Aylward, Minister for Transportation & Infrastructure for PEI. MLA for District 6 Stratford-Keppoch. Tweets in this file start on 2015-03-30. @juliegreenMLA: Julie Green, NWT Minister of Health and Social Services, Minister Responsible for Persons wit... Visit https://dataone.org/datasets/sha256%3A6926de50d5ad28e6d3b4820345ba4dc1b5dd549afa67117940a8819dd53b98cf for complete metadata about this dataset.

BackgroundThe COVID-19 pandemic has highlighted health disparities, especially among specific population groups. This study examines the spatial relationship between the proportion of visible minorities (VM), occupation types and COVID-19 infection in the Greater Vancouver region of British Columbia, Canada.MethodsProvincial COVID-19 case data between June 24, 2020, and November 7, 2020, were aggregated by census dissemination area and linked with sociodemographic data from the Canadian 2016 census. Bayesian spatial Poisson regression models were used to examine the association between proportion of visible minorities, occupation types and COVID-19 infection. Models were adjusted for COVID-19 testing rates and other sociodemographic factors. Relative risk (RR) and 95% Credible Intervals (95% CrI) were calculated.ResultsWe found an inverse relationship between the proportion of the Chinese population and risk of COVID-19 infection (RR = 0.98 95% CrI = 0.96, 0.99), whereas an increased risk was observed for the proportions of the South Asian group (RR = 1.10, 95% CrI = 1.08, 1.12), and Other Visible Minority group (RR = 1.06, 95% CrI = 1.04, 1.08). Similarly, a higher proportion of frontline workers (RR = 1.05, 95% CrI = 1.04, 1.07) was associated with higher infection risk compared to non-frontline.ConclusionDespite adjustments for testing, housing, occupation, and other social economic status variables, there is still a substantial association between the proportion of visible minorities, occupation types, and the risk of acquiring COVID-19 infection in British Columbia. This ecological analysis highlights the existing disparities in the burden of diseases among different visible minority populations and occupation types.

Snapshot img { margin: 10px !important; } This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc.

Overview of Therapeutic Pipeline for COVID-19

The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally.

Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the immune system. Over 26% of the molecules in the pipeline are currently in the pre-clinical stages.

Companies covered

Several companies are involved in the development of pipeline molecules for COVID-19. In addition to the companies, major institutes, universities, and hospitals are also conducting studies on COVID-19. Moreover, companies are collaborating with institutions such as the US Department of Health & Human Services and the University of British Columbia to use the available technologies properly for the further development and commercialization of molecules.

The report covers detailed information on several companies actively involved in the development of molecules for COVID-19 including -

AbbVie Inc.
AIM ImmunoTech Inc.
Ansun BioPharma
APEIRON Biologics AG
Ascletis Pharma Inc.
Blade Therapeutics Inc.
Can-Fite BioPharma Ltd.
CanSino Biologics Inc.
Clover Biopharmaceuticals
F. Hoffmann-La Roche Ltd.
FUJIFILM Corp.
Gilead Sciences Inc.
IMV Inc.
InflaRx GmbH
Inovio Pharmaceuticals Inc.
Johnson & Johnson Services Inc.
Mallinckrodt Plc
Moderna Inc.
NeuroRx Inc.
Novavax Inc.
OncoImmune Inc.
OyaGen Inc.
Pulmotect Inc.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals Inc.
Sanofi
SLA Pharma AG
Sorrento Therapeutics Inc.
Swedish Orphan Biovitrum AB
Symvivo Corp.
Takeda Pharmaceutical Co.
Tonix Pharmaceuticals Holding Corp.
Vanda Pharmaceuticals Inc.
Vaxart Inc.

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Route of Administration

Oral
Intravenous
Nasal
Intradermal
Intramuscular
Unknown

Most of the pipeline molecules for COVID-19 treatment are being developed for oral administration. Additionally, companies and institutions are also focusing on developing drugs that can be delivered through the subcutis (intravenous RoA).

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Therapy

Monotherapy
Combination therapy

Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs.

COVID-19 - Pipeline Analysis: Key Highlights of the Report

What are the therapy molecules used in the various development stages of COVID-19?
What are the companies that are currently involved in the development of therapeutic molecules for COVID-19?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule

We can help! Our analysts can customize this report to meet your requirements. Get in touch

This data is a subset of the Smart Discharges Uganda Under 5 years parent study and is specific to the Phase I observation cohort of children aged 0-6 months collected during the Covid-19 pandemic in 2020. Objective(s): Used as part of the Smart Discharge prediction modelling for adverse outcomes such as post-discharge death and readmission. Data Description: All data were collected at the point of care using encrypted study tablets and these data were then uploaded to a Research Electronic Data Capture (REDCap) database hosted at the BC Children’s Hospital Research Institute (Vancouver, Canada). At admission, trained study nurses systematically collected data on clinical, social and demographic variables. Following discharge, field officers contacted caregivers at 2 and 4 months by phone, and in-person at 6 months, to determine vital status, post-discharge health-seeking, and readmission details. Verbal autopsies were conducted for children who had died following discharge. . Data Processing: Created z-scores for anthropometry variables using height and weight according to WHO cutoff. Distance to hospital was calculated using latitude and longitude. Extra symptom and diagnosis categories were created based on text field in these two variables. BCS score was created by summing all individual components. Limitations: There are missing dates and the admission, discharge, and readmission dates are not in order. Ethics Declaration: This study was approved by the Mbarara University of Science and Technology Research Ethics Committee (No. 15/10-16), the Uganda National Institute of Science and Technology (HS 2207), and the University of British Columbia / Children & Women’s Health Centre of British Columbia Research Ethics Board (H16-02679). This manuscript adheres to the guidelines for STrengthening the Reporting of OBservational studies in Epidemiology (STROBE). NOTE for restricted files: If you are not yet a CoLab member, please complete our membership application survey to gain access to restricted files within 2 business days. Some files may remain restricted to CoLab members. These files are deemed more sensitive by the file owner and are meant to be shared on a case-by-case basis. Please contact the CoLab coordinator at sepsiscolab@bcchr.ca or visit our website.

In view of the challenges of the current coronavirus (COVID 19) pandemic and to protect both patients and ultrasound providers (physicians, sonographers, allied professionals), the International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) has compiled the following expert opinion based guidance for the performance of ultrasound investigations in pregnancy and for gynecological indications. The guidance assumes that robust local processes are in place for cleaning ultrasound equipment after each patient routinely, and gives specific recommendations for ultrasound examinations in suspected or confirmed cases of COVID-19.